Neurology:脑出血周围水肿

2019-08-17 xing.T MedSci原创

由此可见,脑出血周围水肿虽然影响死亡率,但与ICH体积>30mL患者的功能预后较差无关。虽然血肿体积与峰值水肿程度相关,但血肿表面积是水肿进展的主要参数。因此,水肿对功能结局的影响在较小和不规则形状的血肿中更明显,并且这些患者可能特别受益于水肿改善疗法。

近日,神经病学领域权威取杂志Neurology上发表了一篇研究文章,该研究旨在确定脑出血(ICH)位置、体积及血肿表面对出血周围水肿进展的影响。 

研究人员分析了2010年至2013年期间自发性脑出血患者(UKER-ICH)队列研究(NCT03183167)中ICH患者的临床资料。对住院期间的血肿和水肿体积进行了体积评估,水肿进展和峰值水肿的时间过程与血肿体积、位置和表面相关,以验证水肿进展参数的强度。

总体而言,研究人员对300名幕上ICH患者进行了分析。无论血肿位置如何,峰值水肿与血肿表面(R2=0.864,p<0.001)高度相关,而不是与血肿体积高度相关。血肿表面积与体积比率较高的较小血肿表现出与水肿相关性较高(R2=0.755,p<0.001)。多变量logistic回归分析显示ICH体积为30mL作为临界值,超过此范围,总损伤体积(血肿和水肿的总体积)的增加与更差的功能结局无关。具体而言,峰值水肿与ICH<30mL患者的功能转归较差相关(比值比[OR]为2.63,95%可信区间[CI]为1.68-4.12,p<0.001),而在ICH≥30mL患者相反(OR为1.20,95%CI为0.88-1.63,p=0.247)。在调整血肿体积后,脑叶和深部ICH患者之间没有显著差异。

由此可见,脑出血周围水肿虽然影响死亡率,但与ICH体积>30mL患者的功能预后较差无关。虽然血肿体积与峰值水肿程度相关,但血肿表面积是水肿进展的主要参数。因此,水肿对功能结局的影响在较小和不规则形状的血肿中更明显,并且这些患者可能特别受益于水肿改善疗法。 

原始出处:

Maximilian I. Sprügel,et al.Perihemorrhagic edema Revisiting hematoma volume, location, and surface.Neurology.2019.https://n.neurology.org/content/early/2019/08/16/WNL.0000000000008129

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000850, encodeId=0a01200085049, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jun 11 16:11:00 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373534, encodeId=36e03e35349d, content=蛮有启示的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Sat Oct 05 01:29:08 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333448, encodeId=81f913334485e, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Mon Aug 19 06:11:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371405, encodeId=1cbd3e14050a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Aug 17 15:24:28 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
    2020-06-11 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2000850, encodeId=0a01200085049, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jun 11 16:11:00 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373534, encodeId=36e03e35349d, content=蛮有启示的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Sat Oct 05 01:29:08 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333448, encodeId=81f913334485e, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Mon Aug 19 06:11:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371405, encodeId=1cbd3e14050a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Aug 17 15:24:28 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
    2019-10-05 一一一多

    蛮有启示的研究

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2000850, encodeId=0a01200085049, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jun 11 16:11:00 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373534, encodeId=36e03e35349d, content=蛮有启示的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Sat Oct 05 01:29:08 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333448, encodeId=81f913334485e, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Mon Aug 19 06:11:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371405, encodeId=1cbd3e14050a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Aug 17 15:24:28 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
    2019-08-19 小华子
  4. [GetPortalCommentsPageByObjectIdResponse(id=2000850, encodeId=0a01200085049, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jun 11 16:11:00 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373534, encodeId=36e03e35349d, content=蛮有启示的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Sat Oct 05 01:29:08 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333448, encodeId=81f913334485e, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Mon Aug 19 06:11:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371405, encodeId=1cbd3e14050a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Aug 17 15:24:28 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
    2019-08-17 phoebeyan520

    学习了

    0

相关资讯

Lancet Neurol:脑微出血患者抗血小板治疗有益还是有害?

在 RESTART 试验中,脑出血发病前正在抗栓治疗的患者,发生脑出血后开始抗血小板治疗可能能够降低复发性症状性脑出血的风险(vs 未抗血小板治疗)。脑出血和脑小血管病(比如脑微出血)影像学特征与更高的脑出血复发风险有关。

Stroke:深部脑出血患者强化降压与血肿周围水肿扩张

由此可见,强化降压与深部ICH患者24小时PHER降低有关。PHER与所有深部ICH患者的结局无关,但与基底神经节ICH患者的预后不良有关。PHER可能是基底神经节ICH患者临床试验的临床相关终点。

Neurology:低密度脂蛋白胆固醇与脑出血风险

由此可见,当LDL-C<70mg/dL时,研究人员观察到较低LDL-C与较高ICH风险之间存在显著相关性,当LDL-C≥70mg/dL时,这种关联变得不显著。这些数据有助于确定动脉粥样硬化疾病患者和出血性卒中风险增加的患者的理想LDL范围,并指导未来降脂研究的计划。

以脑出血为首发症状的绒毛膜癌脑转移1例

女性,29 岁,因间断头痛5 年、加重1 周并抽搐1 次于2016年11月30日凌晨入院。5年来,病人出现间断头痛,自服止痛片后好转;1周前,自觉头痛加重,仍自服药物,未到医院就诊;2016年11月29日晚突然剧烈头痛,伴有恶心、呕吐数次,同时发生四肢抽搐,伴有双眼上翻,意识不清,数十分钟后自行缓解,急送我院急诊科,头部CT发现右颞脑出血,出血量约25 ml,周围水肿明显(图1A)。既往无高血压病

Neurosurgery:制定脑出血微创手术目标,以达到更佳疗效

微创外科手术,包括立体定向导管rtPA溶解血凝块抽吸和清除血肿,是一项有希望的方法,以改善慕上脑出血的预后,降低致残率。最近发表了一项 III 期随机试验(MISTIE)发现这种方法能够降低死亡率,但是对主要终点未起到作用(1年 mRS 0-3)。

Neurology:脑出血后低血红蛋白与血肿扩大

由此可见,需要进一步的研究来重复低入院血红蛋白水平与ICH后HE介导更差结局可能性增加之间的关联。如果得到证实,可能需要调查血红蛋白水平是否可以作为改善ICH结局的可调整治疗目标。